Source: Fox News
Summary
Gwyneth Paltrow’s podcast featured Dr. Andrew Huberman discussing retatrutide, a new GLP-1 therapy that may offer weight loss with fewer side effects. Unlike older medications, retatrutide is a triple agonist that activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. In clinical trials, retatrutide has shown a lower side effect profile and the ability to help people lose up to a third of their body weight over a year. However, Huberman warned against using unregulated online sources, citing the risk of contamination and inflammation.
Our Reading
The advice sounds familiar.
Retatrutide’s multi-receptor approach may offer a more balanced weight loss solution. However, the growing demand has led to a gray market of unregulated online sources, which can be problematic. The “wild-west” peptide craze raises concerns about safety and efficacy. As with any new therapy, it’s essential to prioritize working with a medical doctor and avoid unverified online sources.
The quest for the perfect weight loss solution continues, with retatrutide being the latest contender. As we’ve seen before, the promise of a quick fix can lead to a gray market of unregulated products. It’s essential to approach these new therapies with a critical eye and prioritize safety above all else.
Author: Evan Null
